SAN DIEGO, Aug. 28, 2018
SAN DIEGO, Aug. 28, 2018 /PRNewswire/ -- Viking Therapeutics, Inc. ("Viking") (NASDAQ: VKTX), a clinical-stage biopharmaceutical company focused on the development of novel therapies for metabolic and endocrine disorders, today announced that the company will participate in three upcoming investor conferences.
B. Riley FBR Annual Healthcare Investor Conference
The company will attend and participate in 1-on-1 meetings at the B. Riley FBR Annual Healthcare Investor Conference, which is being held in New York on September 4, 2018. The conference will take place at the New York Marriott East Side.
H.C. Wainwright 20th Annual Global Investment Conference
Chief executive officer, Brian Lian, Ph.D., will present a corporate overview at the H.C. Wainwright 20th Annual Global Investment Conference, which is being held in New York on September 4-6, 2018.
Details of the presentation are as follows:
Wednesday, Sept. 5 at 10:00 - 10:25 AM ET (webcast available)
The St. Regis, New York
Louis XVI A (2nd Floor)
Citi's 13th Annual Biotech Conference
The company will attend and participate in 1-on-1 meetings at Citi's 13th Annual Biotech Conference, which is being held in Boston on September 5-6, 2018. The conference will take place at the Four Seasons Hotel.
To access the live webcast of the H.C. Wainwright presentation, please visit "Webcasts & Presentations" within the News & Events section of Viking's Investors page at www.vikingtherapeutics.com. Additionally, a replay of the webcast will be available on the Viking website following the conference.
About Viking Therapeutics, Inc.
Viking Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on the development of novel, first-in-class or best-in-class therapies for metabolic and endocrine disorders. The company's research and development activities leverage its expertise in metabolism to develop innovative therapeutics designed to improve patients' lives. The company's clinical programs include VK5211, an orally available, non-steroidal selective androgen receptor modulator. In a Phase 2 trial in patients recovering from hip fracture, patients who received VK5211 experienced significant improvements in measures of lean body mass compared to patients who received placebo. The company's second clinical program is evaluating VK2809, a small molecule thyroid beta agonist in a Phase 2 trial for the treatment of non-alcoholic fatty liver disease and hypercholesterolemia. The company is also developing VK0612, a first-in-class, orally available drug candidate in Phase 2 development for type 2 diabetes. Additional programs include novel and selective agonists of the thyroid beta receptor for GSD Ia and X-linked adrenoleukodystrophy, as well as two earlier-stage programs targeting metabolic diseases and anemia. Viking holds exclusive worldwide rights to a portfolio of five therapeutic programs in clinical trials or preclinical studies, including those noted above, which are based on small molecules licensed from Ligand Pharmaceuticals Incorporated.
Follow Viking on Twitter @Viking_VKTX.
SOURCE Viking Therapeutics, Inc.